Short-term and low-dose prednisolone administration reduces aromatase inhibitor-induced arthralgia in patients with breast cancer

Makoto Kubo, Hideya Ohnishi, Syoji Kuroki, Masayuki Okido, Kazuo Shimada, Kazunori Yokohata, Shuyo Umeda, Takahiro Ogawa, Masao Tanaka, Mitsuo Katano

研究成果: ジャーナルへの寄稿記事

29 引用 (Scopus)

抄録

Aromatase inhibitors (AIs) are important therapeutic drugs for postmenopausal women with hormone receptor-positive breast cancer. However, adverse effects of AIs such as arthralgia have been extensively reported. We performed a joint prospective, multi-institutional investigation to find out whether a low-dose and short-term prednisolone is effective against AI-induced arthralgia in 27 patients with breast cancer. Patients were administered 5 mg of oral prednisolone once a day in the morning for only one week. Patients were then asked to answer a questionnaire about joint pain symptoms at one week, one month and two months after the beginning of prednisolone use. Joint pain symptoms improved in 67% of patients immediately after prednisolone use, with 63% still reporting analgesic effect at one month, and 52% at two months after beginning internal use of prednisolone. At one week, one month and two months after the use of prednisolone, 30%, 30% and 26% of patients reported improved daily life, respectively. Our results suggest that prednisolone could substitute non-steroidal antiinflammatory drugs, acetoaminophen or cyclooxygenase-2 inhibitors in patients with AI-induced arthralgia.

元の言語英語
ページ(範囲)2331-2336
ページ数6
ジャーナルAnticancer research
32
発行部数6
出版物ステータス出版済み - 6 1 2012

Fingerprint

Aromatase Inhibitors
Arthralgia
Prednisolone
Breast Neoplasms
Cyclooxygenase 2 Inhibitors
Pharmaceutical Preparations
Analgesics
Anti-Inflammatory Agents
Joints
Hormones

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

これを引用

Short-term and low-dose prednisolone administration reduces aromatase inhibitor-induced arthralgia in patients with breast cancer. / Kubo, Makoto; Ohnishi, Hideya; Kuroki, Syoji; Okido, Masayuki; Shimada, Kazuo; Yokohata, Kazunori; Umeda, Shuyo; Ogawa, Takahiro; Tanaka, Masao; Katano, Mitsuo.

:: Anticancer research, 巻 32, 番号 6, 01.06.2012, p. 2331-2336.

研究成果: ジャーナルへの寄稿記事

Kubo, M, Ohnishi, H, Kuroki, S, Okido, M, Shimada, K, Yokohata, K, Umeda, S, Ogawa, T, Tanaka, M & Katano, M 2012, 'Short-term and low-dose prednisolone administration reduces aromatase inhibitor-induced arthralgia in patients with breast cancer', Anticancer research, 巻. 32, 番号 6, pp. 2331-2336.
Kubo, Makoto ; Ohnishi, Hideya ; Kuroki, Syoji ; Okido, Masayuki ; Shimada, Kazuo ; Yokohata, Kazunori ; Umeda, Shuyo ; Ogawa, Takahiro ; Tanaka, Masao ; Katano, Mitsuo. / Short-term and low-dose prednisolone administration reduces aromatase inhibitor-induced arthralgia in patients with breast cancer. :: Anticancer research. 2012 ; 巻 32, 番号 6. pp. 2331-2336.
@article{e51c4989ae3148a696618b34ff564145,
title = "Short-term and low-dose prednisolone administration reduces aromatase inhibitor-induced arthralgia in patients with breast cancer",
abstract = "Aromatase inhibitors (AIs) are important therapeutic drugs for postmenopausal women with hormone receptor-positive breast cancer. However, adverse effects of AIs such as arthralgia have been extensively reported. We performed a joint prospective, multi-institutional investigation to find out whether a low-dose and short-term prednisolone is effective against AI-induced arthralgia in 27 patients with breast cancer. Patients were administered 5 mg of oral prednisolone once a day in the morning for only one week. Patients were then asked to answer a questionnaire about joint pain symptoms at one week, one month and two months after the beginning of prednisolone use. Joint pain symptoms improved in 67{\%} of patients immediately after prednisolone use, with 63{\%} still reporting analgesic effect at one month, and 52{\%} at two months after beginning internal use of prednisolone. At one week, one month and two months after the use of prednisolone, 30{\%}, 30{\%} and 26{\%} of patients reported improved daily life, respectively. Our results suggest that prednisolone could substitute non-steroidal antiinflammatory drugs, acetoaminophen or cyclooxygenase-2 inhibitors in patients with AI-induced arthralgia.",
author = "Makoto Kubo and Hideya Ohnishi and Syoji Kuroki and Masayuki Okido and Kazuo Shimada and Kazunori Yokohata and Shuyo Umeda and Takahiro Ogawa and Masao Tanaka and Mitsuo Katano",
year = "2012",
month = "6",
day = "1",
language = "English",
volume = "32",
pages = "2331--2336",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "6",

}

TY - JOUR

T1 - Short-term and low-dose prednisolone administration reduces aromatase inhibitor-induced arthralgia in patients with breast cancer

AU - Kubo, Makoto

AU - Ohnishi, Hideya

AU - Kuroki, Syoji

AU - Okido, Masayuki

AU - Shimada, Kazuo

AU - Yokohata, Kazunori

AU - Umeda, Shuyo

AU - Ogawa, Takahiro

AU - Tanaka, Masao

AU - Katano, Mitsuo

PY - 2012/6/1

Y1 - 2012/6/1

N2 - Aromatase inhibitors (AIs) are important therapeutic drugs for postmenopausal women with hormone receptor-positive breast cancer. However, adverse effects of AIs such as arthralgia have been extensively reported. We performed a joint prospective, multi-institutional investigation to find out whether a low-dose and short-term prednisolone is effective against AI-induced arthralgia in 27 patients with breast cancer. Patients were administered 5 mg of oral prednisolone once a day in the morning for only one week. Patients were then asked to answer a questionnaire about joint pain symptoms at one week, one month and two months after the beginning of prednisolone use. Joint pain symptoms improved in 67% of patients immediately after prednisolone use, with 63% still reporting analgesic effect at one month, and 52% at two months after beginning internal use of prednisolone. At one week, one month and two months after the use of prednisolone, 30%, 30% and 26% of patients reported improved daily life, respectively. Our results suggest that prednisolone could substitute non-steroidal antiinflammatory drugs, acetoaminophen or cyclooxygenase-2 inhibitors in patients with AI-induced arthralgia.

AB - Aromatase inhibitors (AIs) are important therapeutic drugs for postmenopausal women with hormone receptor-positive breast cancer. However, adverse effects of AIs such as arthralgia have been extensively reported. We performed a joint prospective, multi-institutional investigation to find out whether a low-dose and short-term prednisolone is effective against AI-induced arthralgia in 27 patients with breast cancer. Patients were administered 5 mg of oral prednisolone once a day in the morning for only one week. Patients were then asked to answer a questionnaire about joint pain symptoms at one week, one month and two months after the beginning of prednisolone use. Joint pain symptoms improved in 67% of patients immediately after prednisolone use, with 63% still reporting analgesic effect at one month, and 52% at two months after beginning internal use of prednisolone. At one week, one month and two months after the use of prednisolone, 30%, 30% and 26% of patients reported improved daily life, respectively. Our results suggest that prednisolone could substitute non-steroidal antiinflammatory drugs, acetoaminophen or cyclooxygenase-2 inhibitors in patients with AI-induced arthralgia.

UR - http://www.scopus.com/inward/record.url?scp=84864555869&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864555869&partnerID=8YFLogxK

M3 - Article

VL - 32

SP - 2331

EP - 2336

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 6

ER -